Formation Bio

Delighted to share a recently published paper co-authored by Formation Bio team members Luping Zhao, Chris Knight, and Ken Somberg exploring the question: Is it more effective to detect the effects of disease-modifying osteoarthritis treatment on cartilage using MRI scans if researchers know the order of the images? OARSI - Osteoarthritis Research Society International #drugdevelopment #pharma #clinicaldevelopment #DMOAD https://lnkd.in/ddvKMp7K

Formation Bio's Melanie Hullings and Laura Fazio, MS will be presenting at PHUSE on July 25th in Pennsylvania. We hope to see you there! -- In the era of AI and advanced analytics propelling data management forward at an exponential rate, partnership between Clinical Data Managers and Clinical Data Scientists is critical. Laura and Mel will discuss how these teams at Formation Bio work together to create fit-for-purpose tools to automate data cleaning, reporting and analytics. They will also share perspectives on where AI-driven solutions will fit into the clinical data ecosystem and solicit feedback on the gaps that still need filling to support real-time data-driven decisions. More confernece details here: https://rb.gy/r2yctv #datascience #biotech #pharma #drugdevelopment #clinicaltrials #clinicaldatamanagement

Thrilled to be partnering with the Formation Bio team on their Series D fundraise. Formation Bio is building a tech and AI-native pharma company that is radically changing the way drug development is done and making it much more efficient. Benjamine Liu has built a team that brings together the best across pharma, AI, and technology to tackle one of the world’s most challenging problems and bring new treatments to patients faster. I and the full SV Angel team are incredibly excited to be a part of the journey!

Proud to see Formation Bio continue its incredible journey with a $372M Series D. Their AI-driven approach is transforming drug development!

Today we announced our $372MM Series D financing, led by Andreessen Horowitz with major participation from Sanofi. Existing investors also joined this round, including Sequoia Capital, Thrive Capital, Lachy Groom, and Emerson Collective, along with new investors SV Angel Growth and FPV Ventures and others. At Formation Bio, we are building the pharma company of the future, where human expertise and AI collaborate seamlessly to make drug development and clinical trials dramatically more efficient. As AI accelerates drug discovery, generating more promising candidate drugs than ever before, we believe the most consequential bottleneck to bringing more medicines to patients is the staggering cost and time needed for drug development and clinical trials. By designing and developing AI specifically tailored for drug development, we can increase the total number of candidate drugs that can progress through development, and ultimately deliver more new treatments to patients faster and more efficiently. We are proud to partner with best-in-class investors and advisors from both pharma and tech backgrounds along the way. Read more here: https://lnkd.in/et6uKzGV #pharma #biotech #funding #fundraise #tech #ai #drugdevelopment

Today we announced our $372MM Series D financing, led by Andreessen Horowitz with major participation from Sanofi. Existing investors also joined this round, including Sequoia Capital, Thrive Capital, Lachy Groom, and Emerson Collective, along with new investors SV Angel Growth and FPV Ventures and others. At Formation Bio, we are building the pharma company of the future, where human expertise and AI collaborate seamlessly to make drug development and clinical trials dramatically more efficient. As AI accelerates drug discovery, generating more promising candidate drugs than ever before, we believe the most consequential bottleneck to bringing more medicines to patients is the staggering cost and time needed for drug development and clinical trials. By designing and developing AI specifically tailored for drug development, we can increase the total number of candidate drugs that can progress through development, and ultimately deliver more new treatments to patients faster and more efficiently. We are proud to partner with best-in-class investors and advisors from both pharma and tech backgrounds along the way. Read more here: https://lnkd.in/et6uKzGV #pharma #biotech #funding #fundraise #tech #ai #drugdevelopment

We are excited to announce our $372MM Series D financing led by Andreessen Horowitz with major participation from Sanofi. Existing investors Sequoia Capital, Thrive Capital, Lachy Groom, and Emerson Collective also joined the round, along with new investors SV Angel and FPV Ventures. At Formation Bio, we believe that building a culture and team that continuously innovates across the intersection of AI, tech, and pharma is one of our biggest competitive advantages. We are grateful to be working with two organizations at the forefront of AI, tech, and pharma: Andreessen Horowitz and Sanofi. We are excited to welcome Scott Kupor, Managing Partner at a16z and Alfred Lin, Partner at Sequoia to our Board of Directors, alongside existing board director Michael Moritz, Sr. Advisor to Sequoia Heritage and board observer Kareem Zaki, Partner at Thrive Capital. I’m grateful to our team members, advisors, and partners for all of their efforts to get us to where we are today but even more excited to share the journey ahead to create this generation’s tech and AI-native Pharma company. https://lnkd.in/euhi37n7

We are excited to announce our collaboration with OpenAI and Sanofi to build fine-tuned and custom AI solutions to transform drug development. Since our inception, we have focused on building a pharma company differentiated by radical efficiency throughout drug development and clinical trials - and this collaboration helps us advance that vision.    As AI accelerates drug discovery, generating more promising candidate drugs than ever before, we believe the most consequential bottleneck to bringing more medicines to patients is the staggering cost and time needed for drug development and clinical trials. By designing and developing AI specifically tailored for drug development, we can increase the total number of candidate drugs that can progress through development, and ultimately deliver more new treatments to patients faster and more efficiently. You can read more about the collaboration here: https://lnkd.in/eYx9_QYg #ai #drugdevelopment #clinicaltrials #pharma #biotech

We are excited to announce our collaboration with OpenAI and Sanofi to build fine-tuned and custom AI solutions to transform drug development. Since our inception, we have focused on building a pharma company differentiated by radical efficiency throughout drug development and clinical trials - and this collaboration helps us advance that vision.    As AI accelerates drug discovery, generating more promising candidate drugs than ever before, we believe the most consequential bottleneck to bringing more medicines to patients is the staggering cost and time needed for drug development and clinical trials. By designing and developing AI specifically tailored for drug development, we can increase the total number of candidate drugs that can progress through development, and ultimately deliver more new treatments to patients faster and more efficiently. You can read more about the collaboration here: https://lnkd.in/eYx9_QYg #ai #drugdevelopment #clinicaltrials #pharma #biotech

Formation Bio will be attending PharmaSUG 2024! Our team members Helena Belloff Melanie Hullings Andrew Burd Emily Murphy Laura Fazio, MS will be presenting on May 20th and 21st - we hope to see you there! Details below. #software #datascience #pharma #biotech #conference #baltimore #statisticalprogramming #research #clinicaldevelopment #PharmaSUG2024